Petrovax Pharm launches Polyoxidonium^® in drops

Moscow, July 10, 2025 — Petrovax Pharm launched Polyoxidonium^® (azoximer bromide) in its new dosage form of 6 mg drops for topical use. This new product will be available in pharmacies as early as July-August 2025. The new form has been developed for the convenient treatment and prevention of ARVI, influenza, and ENT diseases in adults and children aged 6 months and older^[1].

More than 30 million Russians contract ARVI and influenza each year^[2]. Children under the age of 5 are particularly vulnerable, suffering an average of 6–8 episodes of respiratory viral infections per year^[2].

Experts recommend using immunotropic drugs with proven efficacy in the complex therapy of ARVI and influenza due to the growing resistance of pathogens to etiotropic therapy^[3] and also focus on the activation of mucosal immunity—the first barrier protecting against viruses and bacteria.

Polyoxidonium^® in drops with a dosing pipette attachment has been custom-designed for convenient topical use. The drug facilitates mucosal immune response even in the youngest patients. Unlike other drugs, Polyoxidonium^® has detoxifying properties, acting on the pathogenesis of symptoms^[4].

According to a study involving more than 16,000 patients^[3] Polyoxidonium^® in combination therapy for ENT diseases facilitates quick relief of symptoms of ARVI, such as fever, sore throat, nasal congestion and cough. The drug improves health from the first days^[5], accelerates the relief of catarrhal symptoms by an average of 1.3 days and protects against recurrent episodes of ARVI for up to 3.5 months^{[6], [7]}.

The expert noted that azoximer bromide (Polyoxidonium^®) enhances interferon synthesis and activates natural killer cells (NK cells^[9]), which is pivotal in fighting viruses.

The properties of azoximer bromide have been confirmed in double-blind placebo-controlled studies and post-marketing studies in Russia and the EU. The research data is presented in more than 350 scientific papers.

Polyoxidonium^® is an original medicinal product manufactured by Petrovax Pharm and used in Russia and abroad. Presented as drops, this new dosage form is a convenient and state-of-the-art solution developed with the needs of both patients and physicians (therapists, pediatricians and ENT specialists) in mind, who have long sought this type of product.